Haploidentical hematopoietic cell transplant recipient presents with late-onset Epstein Barr virus-associated posttransplant lymphoproliferative disorder.

Posttransplant lymphoproliferative disease (PTLD) is a potentially life-threatening complication of hematopoietic cell transplantation. With improvements in Epstein-Barr virus (EBV) monitoring and supportive care, PTLD incidence has decreased throughout the history of bone marrow transplantation. It is rare to develop PTLD after the first year following transplant, across all donor categories.